Company intelligence / Profile preview

Simcere Holding

Nanjing, China

Ownership: Private
Development stage: Other

Overview

Simcere has successfully launched multiple innovative products in China including COSELA® (trilaciclib, FDA Breakthrough Therapy designation), Enweida®, Endostar®, and Enlituo®. Recently partnered with Ipsen for global development of SIM0613, an LRRC15-targeting ADC with $1.06B in potential milestone payments.[2][4]

Therapeutic areas: OncologyCardiovascularNeurologyInfectious Diseases
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateRecombinant protein
Industry: Biotech

Partnerships

Ipsen (exclusive global licensing agreement for SIM0613 outside Greater China, announced December 22, 2025)G1 Therapeutics (co-developed COSELA®)

Beyond the preview

Go deeper on Simcere Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Simcere Holding.

Explore the full profile